Primary outcome measures
- Overall Survival (OS) (Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years))
This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
Participants: